Quantifying disease progression in amyotrophic lateral sclerosis |
| |
| Authors: | Neil G. Simon MBBS Martin R. Turner PhD Steve Vucic PhD Ammar Al‐Chalabi PhD Jeremy Shefner MD PhD Catherine Lomen‐Hoerth MD PhD Matthew C. Kiernan DSc |
| |
| Affiliation: | 1. Department of Neurology, University of California, San Francisco, San Francisco, CA;2. Prince of Wales Clinical School, University of New South Wales, Randwick, Australia;3. Neuroscience Research Australia, Randwick, Australia;4. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom;5. Westmead Clinical School, University of Sydney, Sydney, Australia;6. Department of Clinical Neuroscience, King's College London, London, United Kingdom;7. Upstate Medical University, Syracuse, NY;8. Brain and Mind Research Institute, University of Sydney, Sydney, Australia |
| |
| Abstract: | Amyotrophic lateral sclerosis (ALS) exhibits characteristic variability of onset and rate of disease progression, with inherent clinical heterogeneity making disease quantitation difficult. Recent advances in understanding pathogenic mechanisms linked to the development of ALS impose an increasing need to develop strategies to predict and more objectively measure disease progression. This review explores phenotypic and genetic determinants of disease progression in ALS, and examines established and evolving biomarkers that may contribute to robust measurement in longitudinal clinical studies. With targeted neuroprotective strategies on the horizon, developing efficiencies in clinical trial design may facilitate timely entry of novel treatments into the clinic. Ann Neurol 2014;76:643–657 |
| |
| Keywords: | |
|
|
